The mechanism of action, Phase 3 MRCT results and post-market cases of the DFU new drug, Fespixon have been accepted for an oral presentation at WUWHS 2022

Published Date:2022-03-02

Original Link:https://www.onenessbio.com/en/news_detail146_3.htm

Statement
No	1	Date of announcement	2022/03/01	Time of announcement	18:42:36
Subject	The mechanism of action, Phase 3 MRCT results and post-market cases of the DFU new drug, Fespixon have been accepted for an oral presentation at WUWHS 2022
To which item it meets	paragraph 12			Date of events	2022/03/02
Date of institutional investor conference:2022/03/02 Time of institutional investor conference:20:00 (TPE time) Location of institutional investor conference:online Outline of institutional investor conference: (1)The mechanism of action, Phase 3 MRCT results and post-market cases of Fespixon (new drug for diabetic foot ulcers) have been accepted for an oral presentation at WUWHS (World Union of Wound Healing Societies) 2022 on 2nd of March, 2022 (GST 4:00 -6:00 PM). The WUWHS Congress this year will be held as a hybrid conference with virtual and on-site participation due to the global pandemic of COVID-19. (2)The World Union of Wound Healing Societies (WUWHS) is the premier wound care professional association which presents more than 90% of all practicing wound care specialists and important wound care associations in the world. The main purpose of WUWHS is to enhance the practice, education, study and global cooperation in wound healing to deliver the best treatment and care to the patients with acute and chronic wounds. The WUWHS is held every 4 years attended by more than 4,000 wound care specialists. Any other matters that need to be specified: The presentation slides will be made publicly by being uploaded to Market Observation Post System according to the regulation.